TACI, a member of the TNF Receptor superfamily, is expressed in the small intestine, spleen, thymus, peripheral blood leukocytes, activated T cells, and resting B cells. TACI can bind to both APRIL and BAFF, stimulate the activation of transcription factors NF-κB and AP-1, and can mediate the calcineurin-dependent activation of NF-AT (nuclear-factor of activated T cells). TACI also plays a key role in the stimulation of B and T cell function. Soluble TACI inhibits APRIL-stimulated proliferation of primary B cells by blocking the binding of APRIL to the membrane-anchored TACI receptor. Recombinant Human TACI is a soluble 159 amino acid polypeptide (17.8 kDa) comprising the TNFR homologous, cysteine-rich extracellular domain of the TACI protein.

Source: E.coli

Synonyms: Transmembrane activator and CAML interactor, TNFRSF13B

AA Sequence: SGLGRSRRGG RSRVDQEERF PQGLWTGVAM RSCPEEQYWD PLLGTCMSCK TICNHQSQRT CAAFCRSLSC RKEQGKFYDH LLRDCISCAS ICGQHPKQCA YFCENKLRSP VNLPPELRRQ RSGEVENNSD NSGRYQGLEH RGSEASPALP GLKLSADQV

Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses.

Biological Activity: Determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 µg/ml.

Note:

1mg will be provided as 2x500μg.